copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Pipeline – Olema Oncology Learn more about our Phase 3 trial, OPERA-01, investigating palazestrant compared to a common therapy A novel pipeline of breast cancer candidates that work to antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal
Study Details | NCT06016738 | OP-1250 . . . - ClinicalTrials. gov Researchers look for people who fit a certain description, called eligibility criteria Some examples of these criteria are a person's general health condition or prior treatments For general information about clinical research, read Learn About Studies Adult female or male participants
OPERA-01 study for adults with advanced breast cancer The OPERA-01 trial will test how safe and effective the investigational drug palazestrant (OP-1250) is compared to one of the available standard-of-care medications
USOR 23107_OP-1250-301_OPERA-01 *STAR* On hold as of 10 03 2024 . . . A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4 6 inhibitor Therapy (OPERA-01)
Fulvestrant and Anastrozole and Letrozole in Breast Cancer and Advanced . . . This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4 6 inhibitor
OPERA-01 - Victorian Cancer Trials Link This study is comparing the safety and effectiveness of a new drug (called OP-1250) to standard of care hormone therapy in people with ER+, HER2- locally advanced or metastatic breast cancer who have had prior treatment
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+ . . . This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4 6 inhibitor
Poster Title - Olema Palazestrant (OP-1250) is a small molecule oral complete ER antagonist (CERAN) and selective ER degrader (SERD) that binds the ligand-binding domain of ER and completely blocks ER-driven transcriptional activity in both wild-type (ESR1-wt) and mutant (ESR1-mut) forms of ER
Palazestrant (OP-1250), A Complete Estrogen Receptor . . . - PubMed Here we describe palazestrant (OP-1250), a novel, orally bioavailable complete ER antagonist and selective ER degrader OP-1250, like fulvestrant, has no agonist activity on the ER and completely blocks estrogen-induced transcriptional activity